ArticleScientific reports2026
Radiosensitizing effects of silver nanoparticles targeting angiogenesis and matrix metalloproteinase signaling in triple negative breast cancer cell lines.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges.International journal of molecular sciences · 2026Pooled it
- Current Perspectives on Radiosensitizers in Cancer Radiotherapy.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) is a highly aggressive subtype with few treatment options and limited response to radiation therapy due to radioresistance. This study explores the anti-angiogenic and anti-migratory potential of silver nanoparticles (Ag-NPs) as radiosensitizers in TNBC cell lines (MDA-MB-231 and MDA-MB-468). Cells were exposed to Ag-NPs and RT. Cell viability was assessed by MTT and trypan blue exclusion assay. Apoptosis and intracellular reactive oxygen species (ROS) were detected by flow cytometry. Angiogenesis-related genes were evaluated by qPCR, while MMP2 and MMP9 protein levels were determined by western blotting. Cell migration and tube formation were assessed using a scratch assay and an endothelial tube formation assay, respectively. Combination of Ag-NPs with RT exhibited strong synergistic anticancer effects in TNBC cell lines. The combinational treatment significantly enhanced apoptosis and ROS production compared to control and individual treatments. It also reduced VEGFR2 and Tie2 gene expression in both cell lines and decreased MMP2 and MMP9 protein levels in MDA-MB-231 cells. Cell migration and tube formation were significantly impaired in MDA-MB-231 cells exposed to combination therapy. Ag-NPs enhanced the cytotoxic effects of RT in TNBC cell lines by increasing apoptosis and ROS, and suppressing cell migration and angiogenic activity, suggesting their potential as a radiosensitizer to improve therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.